LY2444296

Research use only, not for human use.

LY2444296 (FP3FBZ) is an orally active and selective antagonist of kappa opioid receptor(Ki = 1 nM).

LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ～1 nM. LY2444296 exhibits anti-anxiety like effects.

——

LY2444296 displays anti-anxiety like effects in the EPM test.LY2444296 (3 mg/kg; i.p.; 30 min before U69,593 administration) prevents behavioral and neuroendocrine effects caused by the reference kappa agonist U69,593 in cocaine-na?ve rats.LY2444296 reduces anxiety-like and depressive-like behaviors, as well as CORT release, in rats tested after chronic extended access cocaine self-administration, but not in cocaine-na?ve rats.Animal Model:Adult male Sprague Dawley rats (240–250 g)Dosage:3 mg/kg Administration:Injected intraperitoneally; 30 min before U69,593 administration Result:Prevented behavioral and neuroendocrine effects caused by U69,593 in cocaine-na?ve rats.

——

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

——

——

1346133-11-6

408.44

C24H22F2N2O2

>98% (HPLC)

In Vitro:?Ethanol : 27.5 mg/mL (67.33 mM; Ultrasonic)

NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccc(F)c3)cc2)c(F)c1

——

(-20℃)

With Ice Pack

≥ 2 years